Antonio
Oliver Palomo
Publicacións nas que colabora con Antonio Oliver Palomo (9)
2024
-
Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions
International Journal of Antimicrobial Agents, Vol. 63, Núm. 5
-
Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group
Clinical Microbiology and Infection
2023
-
Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysis
The Lancet Regional Health - Europe, Vol. 34
-
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections
The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 5, pp. 1195-1200
2022
-
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa
The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 10, pp. 2809-2815
-
Selection of AmpC β-Lactamase Variants and Metalloβ- Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/ XDR Pseudomonas aeruginosa Infections
Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 2
2021
-
6-Halopyridylmethylidene Penicillin-Based Sulfones Efficiently Inactivate the Natural Resistance of Pseudomonas aeruginosa to β-Lactam Antibiotics
Journal of Medicinal Chemistry, Vol. 64, Núm. 9, pp. 6310-6328
2020
-
Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection
The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 11, pp. 3209-3217
2019
-
Challenging antimicrobial susceptibility and evolution of resistance (oxa-681) during treatment of a long-term nosocomial infection caused by a pseudomonas aeruginosa ST175 Clone
Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 10